Available Innovations

MBL inhibitors with the potential to be developed as an adjuvant to enhance existing carbapenem antibiotics on the market.

Commercialisation Stories

Portfolio Companies


IP Commercialisation

Mark Ashton
Executive Director, Intellectual Property Commercialisation
Craig Belcher
Senior Director, Commercial Engagement - Health
Ben Phillis
Director, Commercial Engagement - Medical Devices & Drug Delivery
Maher Khaled
Director, Commercial Engagement - Personalised Medicine
Yvonne Booth
Associate Director, Commercial Engagement - Health
Kylie Ellis
Associate Director - Commercial Engagement, Health
Stephen Earl
Director, Commercial Engagement - Therapeutics (Health)

Expertise Commercialisation

Wilma James
Senior Director, Expertise Commercialisation
Paul Stockwell
Contracts Manager

Asset Management

Terry Woodcroft
Senior Director, Asset Management

UQ Expert >

UniQuest has access to over 7000+ UQ researchers with research at or above world standard across 30 research strength areas